After ASH, Amgen Assuages Wall Street Over Kyprolis CV Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech took time to address the recent suspicion that there are more cardiovascular events than previously expected with Kyprolis. But the bottom line is that head-to-head efficacy and safety data against Velcade, another multiple myeloma proteasome inhibitor, simply aren’t available yet.